BLM and cancer: It is noteworthy that our study was the first time that identified BLM, WRN, XPA, and RAD54L germline P/LP alterations in BTC patients, supporting consideration of expanded genetic testing for those with positive family cancer history or early-onset disease (below 45 years old).